



31st Annual Meeting

Friday, November 11, 2016

7:30 – 7:35 a.m. **Presidential Welcome**
Howard L. Kaufman, MD, FACS – *Rutgers Cancer Institute of New Jersey*

Holbrook Edwin Kidd Kohrt, MD, PhD Tribute*

Non-CE Session

7:35 – 8:00 a.m. *Organizers & Speakers*
Daniel S. Chen, MD, PhD – *Genentech*
Amani Makkouk, PhD – *Calithera Biosciences*
Ignacio Melero, MD, PhD – *University of Navarra*
Russell Pachynski, MD – *Washington University School of Medicine*

Update Session: Cancer Immunotherapy Trials Network (CITN): Ten Trials with High Priority Agents in Twenty Five Minutes

0.25 AMA PRA Category 1 Credits™

Chair:

Mac Cheever, MD – *Fred Hutchinson Cancer Research Center*

8:00 – 8:05 a.m. **Anti-PD1 in Merkel Cell Cancer and in Malignancy with HIV, IL7 in Prostate Cancer, Anti-CD40 in Pancreas Cancer**
Mac Cheever, MD – *Fred Hutchinson Cancer Research Center*

8:05 a.m. – 8:10 a.m. **Anti-PD1 in Mycosis Fungoides/Sezary Syndrome**
Michael Khodadoust, MD – *Stanford University*

8:10 a.m. – 8:15 a.m. **IL15 in Solid Tumors**
Jeffrey S. Miller, MD – *University of Minnesota*

8:15 a.m. – 8:20 a.m. **IDO Inhibitor in Ovarian Cancer and Melanoma**
Kunle Odunsi, MD, PhD – *Roswell Park Cancer Institute Center for Immunotherapy*

8:20 a.m. – 8:25 a.m. **Flt3-L with Poly ICLC and Anti-DEC205-NY-ESO-1 in Melanoma**
Nina Bhardwaj, MD, PhD – *The Tisch Cancer Institute at The Mount Sinai Medical Center*

Keynote Address: The Mechanistic Basis of Cancer Immunotherapy

Non-CE Session

8:25 – 8:30 a.m. **Introduction**
Howard L. Kaufman, MD, FACS – *Rutgers Cancer Institute of New Jersey*

8:30 – 9:05 a.m. **The Mechanistic Basis of Cancer Immunotherapy**
Ira Mellman, PhD – *Genentech*

9:05 – 9:10 a.m. **Question & Answer**
Ira Mellman, PhD – *Genentech*



Tumor Microenvironment

2.25 AMA PRA Category 1 Credits™

Co-Chairs:

Mary L. (Nora) Disis, MD – *University of Washington*

Thomas F. Gajewski, MD, PhD – *University of Chicago*

- 9:10 – 9:15 a.m. **Introduction**
Mary (Nora) L. Disis, MD – *University of Washington*
- 9:15 – 9:40 a.m. **Tumor Microenvironment with Clinical Aspect; Impact of Therapeutics on Microenvironment**
George Coukos, MD, PhD – *University Hospital of Lausanne*
- 9:40 – 10:05 a.m. **Immunomodulatory Roles of Lymphatic Vessels in the Tumor Microenvironment**
Melody Swartz, PhD – *University of Chicago*
- 10:05 – 10:25 a.m. *Break*
- 10:25 – 10:50 a.m. **CD4 T Cells as Regulators of Tumor Growth**
Mary (Nora) L. Disis, MD – *University of Washington*
- 10:50 – 11:05 a.m. **Neuropilin-1-Deficient Regulatory T cell-Derived Interferon- γ Drives Infectious Instability and Tumor Clearance**
Abigail E. Overacre – *University of Pittsburgh*
- 11:05 – 11:30 a.m. **Tumor and Host Factors Influencing Immune Regulation Within the Tumor Microenvironment**
Thomas F. Gajewski, MD, PhD – *University of Chicago*
- 11:30 – 11:45 a.m. **CD8 α + Dendritic Cells Regulate Leukemia Antigen-Specific CD8+ T Cell Tolerance**
Justin P. Kline, MD – *University of Chicago*

Late-Breaking Abstract Session I

Non-CE Session

Chair:

Laura S. Wood, RN, MSN OCN – *Cleveland Clinic Taussig Cancer Institute*

- 11:45 – 12:00 p.m. **Computational Identification, Functional Characterization and Antibody Blockade of a New Immune Checkpoint in the TIGIT Family of Interacting Molecules**
John Hunter, PhD – *Compugen USA, Inc.*
- 12:00 – 12:15 p.m. **Combinatorial CD8+ and PD-L1 + Cell Densities Correlate with Response and Improved Survival in NSCLC Patients Treated with Durvalumab**
Sonja Althammer, PhD – *Definiens*
- 12:15 – 1:30 p.m. *Lunch and Poster Viewing*

Update Session: Government Agencies

0.5 AMA PRA Category 1 Credits™

Chair:

James L. Gulley, MD, PhD, FACP – *National Cancer Institute, National Institutes of Health*

- 1:30 – 1:45 p.m. **National Cancer Institute**
T. Kevin Howcroft, PhD – *National Cancer Institute, National Institutes of Health*



1:45 – 2:00 p.m. **U.S. Food & Drug Administration**
Raj K. Puri, MD, PhD – *U.S. Food & Drug Administration*

State-of-the-Art Immunotherapies: Challenges and Opportunities

2.25 AMA PRA Category 1 Credits™

Co-Chairs:

James L. Gulley, MD, PhD, FACP – *National Cancer Institute, National Institutes of Health*
Roy S. Herbst, MD, PhD – *Yale Cancer Center*

2:00 – 2:05 p.m. **Introduction**
James L. Gulley, MD, PhD, FACP – *National Cancer Institute, National Institutes of Health*

2:05 – 2:30 p.m. **Challenges and Opportunities for Immunotherapy in Prostate Cancer**
James L. Gulley, MD, PhD, FACP – *National Cancer Institute, National Institute of Health*

2:30 – 2:55 p.m. **Melanoma: Challenges and Opportunities and the Need for Rational Combinations of Agents**
Patrick Hwu, MD – *University of Texas MD Anderson Cancer Center*

2:55 – 3:05 p.m. **Phase I/II CANON Study: Oncolytic Immunotherapy for the Treatment of Non-muscle Invasive Bladder (NMIBC) Cancer Using Intravesical Coxsackievirus A21**
Nicola E. Annels, BSc, PhD – *University of Surrey*

3:05 – 3:15 p.m. **IL-15 Primes an mTOR-Regulated Gene-expression Program to Prolong Anti-tumor Capacity of Human Natural Killer Cells**
Andreas Lundqvist – *Karolinska Institutet*

3:15 – 3:25 p.m. **Reactivating the Anti-tumor Immune Response by Targeting Innate and Adaptive Immunity in a Phase I/II Study of Intratumoral IMO-2125 in Combination with Systemic ipilimumab in Patients with Anti-PD-1 Refractory Metastatic Melanoma**
Cara Haymaker, PhD – *University of Texas MD Anderson Cancer Center*

3:25 – 3:50 p.m. **Translational Development of Novel Immunotherapies for Hematologic Cancers**
Larry W. Kwak, MD, PhD – *City of Hope National Medical Center*

3:50 – 4:15 p.m. **Lung Cancer: Frontline Cancer, Predictive Markers, and Novel Combinations**
Roy S. Herbst, MD, PhD – *Yale Cancer Center*

4:15 – 4:45 p.m. *Break*

Concurrent Session 1: Metabolic and Age-Associated Dysregulation of Anti-Cancer Immunity

1.5 AMA PRA Category 1 Credits™

Organized in collaboration with the American Society for Cell Biology (ASCB)

Co-Chairs:

Tom Misteli, PhD – *National Cancer Institute, National Institutes of Health*
Graham P. Pawelec, PhD – *University of Tuebingen*

4:45 – 4:50 p.m. **Introduction**
Graham P. Pawelec, PhD – *University of Tuebingen*

4:50 – 5:15 p.m. **The Immune System Strikes Back: T Cells Recognizing Indoleamine 2,3-Dioxygenase (IDO) or PD-L1**
Mads Hald Andersen, PhD – *Herlev University Hospital*



- 5:15 – 5:40 p.m. **Myeloid-Derived Suppressor Cells (MDSC), Age and Cancer**
Dawn Bowdish, PhD – *McMaster University*
- 5:40 – 5:55 p.m. **NAD-Sirt1 Axis is Central to the Unique Immuno-Metabolic Phenotype of Th1/17 Hybrid Cells in Regulating its Enhanced Anti-tumor Potential**
Shilpak Chatterjee, PhD – *Medical University of South Carolina*
- 5:55 – 6:10 p.m. **The Wnt5a-beta-catenin Pathway Triggers a Metabolic Switch that Drives Indoleamine 2,3-Dioxygenase Activity and Dendritic Cell Tolerization in the Melanoma Microenvironment: Optimizing Checkpoint Inhibitor Immunotherapy**
Brent A. Hanks, MD, PhD – *Duke University Medical Center*

Concurrent Session II: Promoting and Measuring Antitumor Immunity

1.25 AMA PRA Category 1 Credits™

Co-Chairs:

Francesco M. Marincola, MD – *Sidra Medical and Research Center*

Jeffrey Schlom, PhD – *National Cancer Institute, National Institutes of Health*

- 4:45 – 4:50 p.m. **Introduction**
Jeffrey Schlom, PhD – *National Cancer Institute, National Institutes of Health*
- 4:50 – 5:10 p.m. **Immunotherapeutics and Analyses of the Peripheral Immunome**
Jeffrey Schlom, PhD – *National Cancer Institute, National Institutes of Health*
- 5:10 – 5:30 p.m. **Vaccines, Tumor Antigens, and Immune Responses**
Lisa H. Butterfield, PhD – *University of Pittsburgh*
- 5:30 – 5:50 p.m. **Deciphering Human T Cell Immune Responses Modulated with Immunotherapy**
Lawrence Fong, MD – *University of California, San Francisco*
- 5:50 – 6:05 p.m. **Immunoscore® Colon Analytical Performance**
Fabienne Hermitte, PhD – *HalioDx*
- 6:05 – 6:10 p.m. **Closing Remarks**
Francesco M. Marincola, MD – *Sidra Medical and Research Center*

Social Activity

- 6:15 – 7:30 p.m. *Poster Reception*



Saturday, November 12, 2016

Update Session: Society Initiatives

- 7:30 – 7:40 a.m. **Immune Biomarkers Task Force Update**
Lisa H. Butterfield, PhD – *University of Pittsburgh*
- 7:40 – 7:55 a.m. **Immunoscore as a Prognostic Marker in Stage I-III Colon Cancer: Results of a SITC-Led Global Validation Study**
Jérôme Galon, PhD – *INSERM – Cordeliers Research Center*

Richard Smalley, MD Memorial Lectureship

.75 AMA PRA Category 1 Credits™

- 7:55 – 8:00 a.m. **Introduction**
Howard L. Kaufman, MD, FACS – *Rutgers Cancer Institute of New Jersey*
- 8:00 – 8:35 a.m. **Smalley Keynote Address: PD-1 Blockade in Cancer Treatment – Immunotherapy Meets Precision Medicine**
Suzanne L. Topalian, MD – *Johns Hopkins University*
- 8:35 – 8:40 a.m. **Question & Answer**
Suzanne L. Topalian, MD – *Johns Hopkins University*

Beyond Single-Agents: The Future of Combination Immunotherapy

2.0 AMA PRA Category 1 Credits™

Co-Chairs:

Drew M. Pardoll, MD, PhD – *Johns Hopkins University*
F. Stephen Hodi, MD – *Dana-Farber Cancer Institute*
Holbrook E. Kohrt, MD, PhD* – *Stanford Cancer Institute*

- 8:40 – 8:45 a.m. **Introduction**
F. Stephen Hodi, MD – *Dana-Farber Cancer Institute*
- 8:45 – 9:10 a.m. **Combination Development**
Ignacio Melero, MD, PhD – *University of Navarra*
- 9:10 – 9:35 a.m. **Next Generation Anti-CTLA-4 Antibodies**
Alan J. Korman, PhD – *Bristol-Myers Squibb Company*
- 9:35 – 10:00 a.m. **Combination in Patient Selection**
Jérôme Galon, PhD – *INSERM – Cordeliers Research Center*
- 10:00 – 10:20 a.m. *Break*
- 10:20 – 10:40 a.m. **Combinations and Influences on Biomarkers**
Drew M. Pardoll, MD, PhD – *Johns Hopkins University*
- 10:40 – 10:55 a.m. **Clinical Safety and Efficacy Assessment of the CD137 Agonist Urelumab Alone and in Combination with Nivolumab in Patients with Hematologic and Solid Tumor Malignancies**
Erminia Massarelli, MD, PhD, MS – *City of Hope*
- 10:55 – 11:10 a.m. **Beyond Immune Checkpoint: First-in-Class Antibody Targeting Soluble NKG2D Ligand sMIC for Cancer Immunotherapy**
Jennifer Wu, PhD – *Medical University of South Carolina*



11:10 – 11:15 a.m. **Closing Remarks**
Drew M. Pardoll, MD, PhD – *Johns Hopkins University*

Late-Breaking Abstract Session II

Non-CE Session

Chair: Elizabeth A. Repasky, PhD – *Roswell Park Cancer Institute*

11:15 – 11:30 a.m. **Preliminary Efficacy from a Phase I/II Study of the Natural Killer Cell-Targeted Antibody, Lirilumab in Combination with Nivolumab in Squamous Cell Carcinoma of the Head and Neck**
Rom Leidner, MD – *Earl A. Chiles Research Institute, Providence Cancer Center*

11:30 – 11:45 a.m. **Efficacy and Safety of Nivolumab Plus Ipilimumab in Metastatic Urothelial Carcinoma: First Results From the Phase I/II CheckMate 032 Study**
Padmanee Sharma, MD, PhD – *University of Texas MD Anderson Cancer Center*

11:45 – noon **KEYNOTE-045: Open-label, Phase 3 Study of Pembrolizumab versus Investigator's Choice of Paclitaxel, Docetaxel, or Vinflunine for Previously Treated Advanced Urothelial Cancer**
Joaquim Bellmunt, MD, PhD – *Dana-Farber, Brigham and Women's Cancer Center, Harvard Medical School*

Noon – 1:00 p.m. *Lunch and Poster Viewing*

Concurrent Session I: Presidential Session

1.25 AMA PRA Category 1 Credits™

Chair:

Howard L. Kaufman, MD, FACS – *Rutgers Cancer Institute of New Jersey*

1:00 – 1:05 p.m. **Introduction**
Howard L. Kaufman, MD, FACS – *Rutgers Cancer Institute of New Jersey*

1:05 – 1:20 p.m. **Intestinal Microbiota and Relapse after Hematopoietic-cell Transplantation**
Jonathan Peled, MD, PhD – *Memorial Sloan Kettering Cancer Center*

1:20 – 1:35 p.m. **Mitochondrial Biogenesis is Repressed in Tumor-infiltrating CD8+ T cells Resulting in Metabolic Insufficiency and T Cell Dysfunction**
Nicole E. Scharping – *University of Pittsburgh*

1:35 – 1:45 p.m. **Expert Discussant**
Drew M. Pardoll, MD, PhD – *Johns Hopkins University*

1:45 – 2:00 p.m. **Increased STAT3 Signaling and Decreased Suppressive Function of Regulatory T Cells are Biomarkers of Positive Patient Outcome to Nivolumab Therapy**
David M. Woods, PhD – *New York University*

2:00 – 2:15 p.m. **Analysis of Pharmacodynamic Biomarkers in the First In-Human Trial of GITR Co-Stimulation with the Agonist Antibody TRX-518 in Advanced Solid Cancer Patients**
Roberta Zappasodi, PhD – *Memorial Sloan Kettering Cancer Center*

2:15 – 2:25 p.m. **Expert Discussant**
Jeffrey Schlom, PhD – *National Cancer Institute, National Institutes of Health*



Concurrent Session II: Tumor Immunology 101 (Nurse/Pharmacist Track)

1.5 AMA PRA Category 1 Credits™

Co-Chairs:

Satiro N. De Oliveira, MD – *University of California, Los Angeles*

Paul M. Sondel, MD, PhD – *University of Wisconsin, Madison*

- 1:00 – 1:05 p.m. **Introduction**
Paul M. Sondel, MD, PhD – *University of Wisconsin, Madison*
- 1:05 – 1:30 p.m. **Immunology 101 for the Non-Immunologist**
Christian Capitini, MD – *University of Wisconsin, Madison*
- 1:30 – 1:55 p.m. **Basic Principles of Tumor Immunotherapy**
Satiro N. De Oliveira, MD – *University of California Los Angeles*
- 1:55 – 2:20 p.m. **Tumor Immunotherapy on the Horizon**
Paul M. Sondel, MD, PhD – *University of Wisconsin, Madison*
- 2:20 – 2:25 p.m. **Closing Remarks**
Satiro N. De Oliveira, MD – *University of California Los Angeles*
- 2:25 – 2:40 p.m. *Break*

Concurrent Session I: Microbiome and the Impact on Local Inflammation and Host Immunity

1.75 AMA PRA Category 1 Credits™

Co-Chairs:

Lisa M. Coussens, PhD – *Oregon Health and Science University*

Heidi H. Kong, MD, MHSc – *National Cancer Institute, National Institutes of Health*

- 2:40 – 2:45 p.m. **Introduction**
Heidi H. Kong, MD, MHSc – *National Cancer Institute, National Institutes of Health*
- 2:45 – 3:10 p.m. **Microbial Modulation of Mononuclear Phagocytes in Cancer Therapy**
Romina Goldszmid, PhD – *National Cancer Institute, National Institutes of Health*
- 3:10 – 3:35 p.m. **Influence of Microbiome on Efficacy of Anti-Cancer Therapy**
María Paula Roberti, PhD – *Institute Gustave Roussy*
- 3:35 – 4:00 p.m. **Inflammation Fuels Microbial Carcinogenic Activities**
Christian Jobin, PhD – *University of Florida*
- 4:00 – 4:15 p.m. **Pre-existing Immunity to Oncolytic Virus Potentiates its Therapeutic Efficacy**
Jacob Ricca – *Memorial Sloan Kettering Cancer Center*
- 4:15 – 4:20 p.m. **Closing Remarks**
Lisa M. Coussens, PhD – *Oregon Health and Science University*



Concurrent Session II: Clinical Management (Nurse/Pharmacist Track)

1.75 AMA PRA Category 1 Credits™

Co-Chairs:

Matthew Burke, MBA, RN, MSN, APRN-B – *Stanford Health Care*

Laura S. Wood, RN, MSN OCN – *Cleveland Clinic Taussig Cancer Institute*

- 2:40 – 2:45 p.m. **Introduction**
Laura S. Wood, RN, MSN OCN – *Cleveland Clinic Taussig Cancer Institute*
- 2:45 – 3:05 p.m. **Immunotherapy Agents Currently Approved for the Treatment of Cancer**
Kristen Kreamer, CRNP, MSN, AOCNP, APRN-BC – *Fox Chase Cancer Center*
- 3:05 – 3:25 p.m. **Assessment & Management of irAEs**
Krista M. Rubin, MS, FNP-BC – *Massachusetts General Hospital Cancer Center*
- 3:25 – 3:45 p.m. **Management of Complex Adverse Events: Case Studies**
Brianna W. Hoffner, BA, MSN, RN, ANP-BC – *University of Colorado Cancer Center*
- 3:45 – 4:00 p.m. **Incidence and Outcomes of Central Nervous System Metastasis in Metastatic Melanoma Patients Treated with Anti-PD1 Therapy**
Gustavo Schvartsman, MD – *University of Texas MD Anderson Cancer Center*
- 4:00 – 4:15 p.m. **Audience Question & Answer**
Moderator: Laura S. Wood, RN, MSN OCN – *Cleveland Clinic Taussig Cancer Institute*
- 4:15 – 4:20 p.m. **Closing Remarks**
Laura S. Wood, RN, MSN OCN – *Cleveland Clinic Taussig Cancer Institute*
- 4:20 – 4:50 p.m. *Break*

Concurrent Session I: Diet, Exercise, Stress and the Impact on the Immune System

1.5 AMA PRA Category 1 Credits™

Organized in collaboration with the Society of Behavioral Medicine (SBM)

Co-Chairs:

Elizabeth A. Repasky, PhD – *Roswell Park Cancer Institute*

Connie J. Rogers, PhD, MPH – *Pennsylvania State University*

- 4:50 – 4:55 p.m. **Introduction**
Connie J. Rogers, PhD, MPH – *Pennsylvania State University*
- 4:55 – 5:15 p.m. **Changes in Energy Balance Modulate the Immune Response in Breast Cancer Risk & Progression**
Connie J. Rogers, PhD, MPH – *Pennsylvania State University*
- 5:15 – 5:35 p.m. **Research in Behavior in Cancer and Cancer Treatment**
Dana H. Bovbjerg, PhD – *University of Pittsburgh Cancer Institute*
- 5:35 – 5:55 p.m. **Effects of Behavioral Stress on the Tumor Microenvironment**
Susan K. Lutgendorf, PhD – *University of Iowa*
- 5:55 – 6:10 p.m. **β-Adrenergic Signaling Induced by Cool Housing Temperatures Mediates Immune Suppression and Impairs the Efficacy of Anti-PD-1 Checkpoint Blockade Immunotherapy in Laboratory Mice**
Mark J. Bucsek – *Roswell Park Cancer Institute*



6:10 – 6:15 p.m. **Closing Remarks**
Elizabeth A. Repasky, PhD – *Roswell Park Cancer Institute*

Concurrent Session II: Adoptive Cellular Therapy vs. Bispecific Antibodies

1.5 AMA PRA Category 1 Credits™

Co-Chairs:

Crystal L. Mackall, MD – *Stanford University*

Stanley R. Riddell, MD – *Fred Hutchinson Cancer Research Center*

4:50 – 4:55 p.m. **Introduction**
Crystal L. Mackall, MD – *Stanford University*

4:55 – 5:15 p.m. **CARs - CD19 and Beyond**
Crystal L. Mackall, MD – *Stanford University*

5:15 – 5:35 p.m. **Bispecific T Cell Engagers, Biology and Clinical Application**
Max S. Topp, MD – *Universitätsklinikum Würzburg*

5:35 – 5:55 p.m. **CAR Designs for Safe and Effective T Cell Therapy**
Stanley R. Riddell, MD – *Fred Hutchinson Cancer Research Center*

5:55 – 6:10 p.m. **Clinical Responses in Advanced Pancreatic Patients Treated with Bispecific Antibody Armed T Cells (BATS)**
Lawrence G. Lum, MD, DSc – *University of Virginia Cancer Center*

6:10 – 6:15 p.m. **Closing Remarks**
Stanley R. Riddell, MD – *Fred Hutchinson Cancer Research Center*

Concurrent Session III: Emerging Technologies

Non-CE Session

Co-Chairs:

Edward C. Stack, PhD – *PerkinElmer*

David A. Zaharoff, PhD – *University of North Carolina, Chapel Hill & North Carolina State University*

4:50 – 4:55 p.m. **Introduction**
Edward C. Stack, PhD – *PerkinElmer*

4:55 – 5:20 p.m. **Understanding T Cells, Macrophages, and Expression of PD-1/PD-L1 in Hodgkin's Lymphoma**
Scott J. Rodig, MD, PhD – *Brigham and Women's Hospital, Harvard Medical School*

5:20 – 5:40 p.m. **Eradication of Large Established Tumors by Combination Immunotherapy Engaging Innate and Adaptive Immunity**
Darrell J. Irvine, PhD – *Massachusetts Institute of Technology*

5:40 – 5:55 p.m. **Mechanisms of Chitosan/IL-12 Immunotherapy for the Treatment of Bladder Cancer**
Sean G. Smith – *University of North Carolina - Chapel Hill & North Carolina State University*

5:55 – 6:10 p.m. **ImmunoMap: A Novel Bioinformatics Tool for Analysis of T cell Receptor Repertoire Data in Model Systems and Clinical Settings**
John-William Sidhom – *Johns Hopkins University*



6:10 – 6:15 p.m.

Closing Remarks

David A. Zaharoff, PhD – *University of North Carolina - Chapel Hill & North Carolina State University*

Social Activities

6:15 – 6:45 p.m.

Award Ceremony

6:45 – 8:00 p.m.

Poster Reception



Value of Cancer Immunotherapy Summit

Organized in collaboration with the American Society of Clinical Oncology (ASCO)

Sunday, November 13, 201

Non CE-session

Co-Chairs:

Michael B. Atkins, MD – *Georgetown-Lombardi Comprehensive Cancer Center*

Howard L. Kaufman, MD, FACS – *Rutgers Cancer Institute of New Jersey*

Lowell E. Schnipper, MD – *Beth Israel Deaconess Medical Center*

Peter P. Yu, MD, FACP, FASCO – *Hartford HealthCare Cancer Institute*

7:45 – 7:50 a.m.

Annual Meeting Organizer Welcome

James L. Gulley, MD, PhD, FACP – *National Cancer Institute, National Institute of Health*

7:50 – 8:00 a.m.

Program Introduction

Howard L. Kaufman, MD, FACS – *Rutgers Cancer Institute of New Jersey*

Session I: Current Landscape of Cancer Therapy Value Models, Economic Outcomes, and the Patient Perspective

8:00 – 8:30 a.m.

Evaluation of Current Value Models

Peter P. Yu, MD, FACP, FASCO – *Hartford HealthCare Cancer Institute*

8:30 – 8:45 a.m.

Cancer Immunotherapy Perspective on Current Value Models

Michael B. Atkins, MD – *Georgetown-Lombardi Comprehensive Cancer Center*

8:45 – 9:05 a.m.

Economic Outcomes of Cancer Therapy: ISPOR Initiatives on U.S. Value Assessment Framework

Lou Garrison, PhD, AB – *University of Washington*

9:05 – 9:25 a.m.

Patient Perspective

Steven Silverstein, MBA – *Melanoma Research Foundation*

9:25 – 9:45 a.m.

Patient Outcomes Perspective: Patient Reported Outcomes & Personal Cost of Cancer

Adam P. Dicker, MD, PhD – *Thomas Jefferson University*

Heather S. Jim, PhD – *H. Lee Moffitt Cancer Center & Research Institute*

9:45 – 10:10 a.m.

Panel Discussion

Moderator:

Howard L. Kaufman, MD, FACS – *Rutgers Cancer Institute of New Jersey*

Panelists:

Michael B. Atkins, MD – *Georgetown-Lombardi Comprehensive Cancer Center*

Adam P. Dicker, MD, PhD – *Thomas Jefferson University*

Lou Garrison, PhD, AB – *University of Washington*

Heather S. Jim, PhD – *H. Lee Moffitt Cancer Center & Research Institute*

Steven Silverstein, MBA – *Melanoma Research Foundation*

Peter P. Yu, MD, FACP, FASCO – *Hartford HealthCare Cancer Institute*



Session II: Perspectives on the Value of Cancer Immunotherapy

10:10 – 10:30 a.m.	Payor Perspective William McGivney, PhD – <i>McGivney Global Advisors</i>
10:30 – 10:50 a.m.	Industry Perspective Jon M. Wigginton, MD – <i>MacroGenics, Inc.</i>
10:50 – 11:10 a.m.	Predictive and Companion Biomarkers Roy S. Herbst, MD, PhD – <i>Yale Cancer Center</i>
11:10 – 11:55 a.m.	Panel Discussion <i>Moderator:</i> Michael B. Atkins, MD – <i>Georgetown-Lombardi Comprehensive Cancer Center</i> <i>Panelists:</i> Kirsten Axelsen, MS – <i>Pfizer</i> Daniel S. Chen, MD, PhD – <i>Genentech</i> Ravinder Dhawan, PhD – <i>Merck & Co</i> Roy S. Herbst, MD, PhD – <i>Yale Cancer Center</i> Gregory Keenan, MD – <i>AstraZeneca</i> William McGivney, PhD – <i>McGivney Global Advisors</i> Jon M. Wigginton, MD – <i>MacroGenics, Inc.</i>
11:55 – noon	Closing Remarks

**Holbrook Edwin Kidd Kohrt, MD, PhD (1977-2016)*

Dr. Kohrt had a significant impact on the field and brought his considerable scientific insights and incredible energy to every project. He was committed to the field of tumor immunology and immunotherapy and to the mission of SITC. Dr. Kohrt was actively involved in the development of SITC's 31st Annual Meeting as an Organizer and session Co-Chair up until the time of passing. As such, the 31st Annual Meeting will contain a fitting tribute to his memory and his many contributions to the field.